The US Department of Health and Human Services, subjected to numerous changes in leadership over the past two years, is hoping to retain their current staff after the recent US midterm elections, according to Eric Hargan, HHS Deputy Secretary. Hagan addressed Provision Policy’s Biopharma Congress in November of 2018, stating that HHS is hoping to move its drug pricing agenda forward with its current staff in place, under the leadership of HHS Secretary Alex Azar. Read more about what’s in store for HHS here.
Equitable Access to High-Cost Pharmaceuticals
- Book
